Table 2.
Efficacy of Initial Antifungal Treatment for Cryptococcosis of Different Sites
| Initial Antifungal Treatment | Median Duration (range), d | CR | PR | Stable | Progression | Death | Successful Response Rate, % |
|---|---|---|---|---|---|---|---|
| Total (n = 46) | 26 (7–350) | 1 | 29 | 9 | 6 | 1 | 65.2 |
| CM (n = 35) | 21 (7–142) | 1 | 19 | 9 | 5 | 1 | 57.1 |
| AmB ± FC (n = 7)a | 26 (7–127) | 0 | 7 | 0 | 0 | 0 | 100.0 |
| FCZ ± FC (n = 12) | 43 (7–142) | 1 | 6 | 4 | 1 | 0 | 58.3 |
| AmB + FCZ ± FC (n = 5)b | 32 (14–77) | 0 | 4 | 1 | 0 | 0 | 80.0 |
| Other regimens (n = 11)c | 18 (7–73) | 0 | 2 | 4 | 4 | 1 | 18.2 |
| PC alone (n = 9) | 88 (11–350) | 0 | 8 | 0 | 1 | 0 | 88.9 |
| FCZ (n = 7) | 91 (14–350) | 0 | 7 | 0 | 0 | 0 | 100.0 |
| Other regimens (n = 2)d | 19.5 (11–28) | 0 | 1 | 0 | 1 | 0 | 50.0 |
| Other extrapulmonary cryptococcosis (n = 2) | 28 (27–28) | 0 | 2 | 0 | 0 | 0 | 100.0 |
| AmB (n = 1) | 28 | 0 | 1 | 0 | 0 | 0 | 100.0 |
| FCZ + FC (n = 1) | 27 | 0 | 1 | 0 | 0 | 0 | 100.0 |
Abbreviations: ±, with or without; AmB, amphotericin B; CM, cryptococcal meningitis; CR, complete response; FC, flucytosine; FCZ, fluconazole; PC, pulmonary cryptococcosis; PR, partial response.
aMedian daily and accumulative dose of AmB in this group was 0.38 (range, 0.33–0.50) mg/kg and 1636 (range, 224–3354) mg, respectively.
bMedian daily and accumulative dose of AmB in this group was 0.39 (range, 0.35–0.45) mg/kg/day and 1483 (range, 26–5704) mg, respectively.
cOther regimens administered in patients with CM included involvement of itraconazole (n = 5), voriconazole (n = 3), and liposomal AmB–based treatment (n = 2); 1 case was not available.
dOther regimens administered in patients with PC included 1 patient with liposomal AmB plus fluconazole, and another with voriconazole.